Sentiment-Signal
21,2
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 29.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 16.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 13.01.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Unternehmen & Branche
| Name | Definium Therapeutics, Inc. |
|---|---|
| Ticker | DFTX |
| CIK | 0001813814 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2833 · Medicinal Chemicals & Botanical Products |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,04 Mrd. USD |
| Beta | 2,56 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -183,793,000 | -2.06 | 440,100,000 | 332,327,000 | |
| 2025-09-30 | 10-Q | -67,265,000 | -0.78 | 236,916,000 | 130,596,000 | |
| 2025-06-30 | 10-Q | -42,744,000 | -0.50 | 265,091,000 | 185,400,000 | |
| 2025-03-31 | 10-Q | -23,348,000 | -0.35 | 275,323,000 | 222,806,000 | |
| 2024-12-31 | 10-K | -108,679,000 | -1.54 | 302,151,000 | 241,448,000 | |
| 2024-09-30 | 10-Q | -13,684,000 | -0.27 | 319,769,000 | 262,193,000 | |
| 2024-06-30 | 10-Q | -5,854,000 | -0.26 | 268,145,000 | 202,047,000 | |
| 2024-03-31 | 10-Q | -54,400,000 | -1.14 | 275,533,000 | 196,059,000 | |
| 2023-12-31 | 10-K | -95,732,000 | -2.44 | 124,541,000 | 78,134,000 | |
| 2023-09-30 | 10-Q | -17,923,000 | -0.45 | 141,550,000 | 95,979,000 | |
| 2023-06-30 | 10-Q | -29,130,000 | -0.76 | 142,085,000 | 105,972,000 | |
| 2023-03-31 | 10-Q | -24,815,000 | -0.65 | 155,529,000 | 130,344,000 | |
| 2022-12-31 | 10-K | -56,796,000 | -1.84 | 169,993,000 | 150,917,000 | |
| 2022-09-30 | 10-Q | -16,485,000 | -0.56 | 180,907,000 | 153,593,000 | |
| 2022-06-30 | 10-Q | -16,957,000 | -0.60 | 134,277,000 | 124,504,000 | |
| 2022-03-31 | 10-Q | -18,451,000 | -0.66 | 149,234,000 | 136,805,000 | |
| 2021-12-31 | 10-K | -93,036,000 | -3.40 | 164,002,000 | 151,664,000 | |
| 2021-09-30 | 10-Q | -17,196,000 | -0.61 | 164,271,000 | ||
| 2021-06-30 | 10-Q | -45,252,000 | -0.11 | 171,633,000 | ||
| 2021-03-31 | 10-Q | -13,759,000 | 180,594,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-26 | Barrow Robert | Director, Officer, Chief Executive Officer | Open Market Sale | -25,791 | 13.15 | -339,071.70 | -232,9% | |
| 2025-12-26 | Sullivan Mark | Officer, Chief Legal Officer | Open Market Sale | -11,276 | 13.15 | -148,244.44 | -101,8% | |
| 2025-12-26 | Karlin Daniel | Officer, Chief Medical Officer | Open Market Sale | -5,600 | 13.15 | -73,622.64 | -50,6% | |
| 2025-09-25 | Karlin Daniel | Officer, Chief Medical Officer | Open Market Sale | -7,704 | 9.77 | -75,268.08 | -51,7% | |
| 2025-09-25 | Sullivan Mark | Officer, Chief Legal Officer | Open Market Sale | -11,278 | 9.77 | -110,186.06 | -75,7% | |
| 2025-09-25 | Barrow Robert | Director, Officer, Chief Executive Officer | Open Market Sale | -25,797 | 9.77 | -252,036.69 | -173,1% | |
| 2025-06-25 | Sullivan Mark | Officer, Chief Legal Officer | Open Market Sale | -11,491 | 6.80 | -78,138.80 | -53,7% | |
| 2025-06-25 | Barrow Robert | Director, Officer, Chief Executive Officer | Open Market Sale | -26,491 | 6.80 | -180,138.80 | -123,8% | |
| 2025-06-25 | Karlin Daniel | Officer, Chief Medical Officer | Open Market Sale | -7,848 | 6.80 | -53,366.40 | -36,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.